Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Catalyst Pharmaceuticals (CPRX) Enterprise Value (2016 - 2025)

Catalyst Pharmaceuticals' Enterprise Value history spans 16 years, with the latest figure at -$709.2 million for Q4 2025.

  • For Q4 2025, Enterprise Value fell 37.02% year-over-year to -$709.2 million; the TTM value through Dec 2025 reached -$709.2 million, down 37.02%, while the annual FY2025 figure was -$709.2 million, 37.02% down from the prior year.
  • Enterprise Value reached -$709.2 million in Q4 2025 per CPRX's latest filing, down from -$689.9 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$121.0 million in Q3 2023 to a low of -$709.2 million in Q4 2025.
  • Average Enterprise Value over 5 years is -$325.1 million, with a median of -$238.4 million recorded in 2022.
  • Peak YoY movement for Enterprise Value: skyrocketed 53.87% in 2023, then tumbled 276.03% in 2024.
  • A 5-year view of Enterprise Value shows it stood at -$191.3 million in 2021, then plummeted by 56.01% to -$298.4 million in 2022, then surged by 53.87% to -$137.6 million in 2023, then crashed by 276.03% to -$517.6 million in 2024, then tumbled by 37.02% to -$709.2 million in 2025.
  • Per Business Quant, the three most recent readings for CPRX's Enterprise Value are -$709.2 million (Q4 2025), -$689.9 million (Q3 2025), and -$652.8 million (Q2 2025).